Shares

8 transactions
Quarter Operation Price Per share shares change shares Held SEC Form
Q1 2022

May 10, 2022

SELL
$0.9 - $8.39 $9,018 - $84,067
-10,020 Closed
0 $0
Q4 2021

Feb 08, 2022

BUY
$6.58 - $8.44 $65,931 - $84,568
10,020 New
10,020 $80,000
Q1 2020

May 15, 2020

SELL
$5.25 - $9.9 $56,043 - $105,682
-10,675 Closed
0 $0
Q4 2019

Feb 12, 2020

BUY
$5.84 - $10.51 $805 - $1,450
138 Added 1.31%
10,675 $106,000
Q3 2019

Nov 12, 2019

SELL
$5.76 - $9.44 $4,654 - $7,627
-808 Reduced 7.12%
10,537 $61,000
Q2 2019

Aug 13, 2019

SELL
$9.1 - $15.55 $16,443 - $28,098
-1,807 Reduced 13.74%
11,345 $103,000
Q1 2019

May 15, 2019

BUY
$12.5 - $18.48 $29,150 - $43,095
2,332 Added 21.55%
13,152 $182,000
Q4 2018

Feb 14, 2019

BUY
$15.25 - $22.4 $165,005 - $242,367
10,820 New
10,820 $171,000

Others Institutions Holding PRQR

About ProQR Therapeutics N.V.


  • Ticker PRQR
  • Exchange NASDAQ
  • Sector Healthcare
  • Industry Biotechnology
  • Shares Outstandng 71,362,096
  • Market Cap $99.9M
  • Description
  • ProQR Therapeutics N.V., a biopharmaceutical company, engages in the discovery and development of RNA-based therapeutics for the treatment of genetic disorders. It primarily develops sepofarsen that is in phase II/III clinical trial illuminate trial for treating leber congenital amaurosis 10 disease; and ultevursen, which is in phase II/III clin...
More about PRQR
Track This Portfolio

Track Pro Share Advisors LLC Portfolio

Follow Pro Share Advisors LLC and customize your updates to receive the information that matters most to you.

Portfolio Update

Get notified when there are updates to the investment portfolio of Pro Share Advisors LLC, based on Form 13F filings with the SEC.

News

Stay updated on Pro Share Advisors LLC with notifications on news.